New combo attack on liver cancer: immunotherapy plus targeted artery therapies
NCT ID NCT07380633
First seen Feb 02, 2026 · Last updated Apr 30, 2026 · Updated 7 times
Summary
This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three different artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the cancer. About 90 adults with unresectable liver cancer and adequate liver function are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Conditions
Explore the condition pages connected to this study.